Arb clinical trials

Explore recruiting arb clinical trials.

Recruiting arb studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Arb trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A multi-center, randomized, placebo- and active-controlled, parallel-group, 24-week proof of concept and dose-finding study to evaluate efficacy, safety, and tolerability of XXB750 in patients with heart failure

Netherlands, Italy, Bulgaria, Spain, Denmark, Portugal +5 more

Therapeutic exploratory (Phase II) EU CTIS Study details

A pivotal Phase 3, multicenter, randomized, double-blind, placebo-controlled study of the efficacy and safety of DMX-200 in patients with focal segmental glomerulosclerosis (FSGS) who are receiving an angiotensin II receptor blocker (ARB)

France, Spain, Denmark, Germany, Italy, Portugal +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

(19920) A 6-month multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and PK/PD of an age-and body weightadjusted oral finerenone regimen, in addition to an ACEI or ARB, for the treatment of children, 6 months to <18 years of age, with chronic kidney disease and proteinuria

Hungary, Spain, Sweden, France, Greece, Finland +11 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

(20186 - FIONA OLE) An 18-month, open-label, single-arm safety extension study of an age-and bodyweight-adjusted oral finerenone regimen, in addition to an ACEI or ARB, for the treatment of children and young adults from 1 to 18 years of age with chronic kidney disease and proteinuria

France, Hungary, Portugal, Austria, Finland, Denmark +11 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Pharmacological optimization in prevention in Heart Failure: A Sex-gap? (PopS-HF Trial)

Italy

Therapeutic use (Phase IV) EU CTIS Study details

A Phase II, Multi-center, Open-Label Study to Assess Safety, Tolerability, Efficacy and Pharmacokinetics of R3R01 in Alport Syndrome Patients with Uncontrolled Proteinuria on ACE/ARB Inhibition and in Patients with Primary Steroid-Resistant Focal Segmental Glomerulosclerosis

France, Belgium, Netherlands, Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

Arb trials by city

Arb in Toronto Arb in Vancouver Arb in Montreal Arb in Calgary Arb in Edmonton Arb in Ottawa Arb in Winnipeg Arb in Quebec City Arb in Hamilton Arb in Kitchener Arb in London Arb in Halifax Arb in New York Arb in Los Angeles Arb in Chicago Arb in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease